Drug Development Drug Pricing Pharmaceutical Companies 
Pharmaceutical Technology
MAY 17, 2023
The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drug pricing provisions. While negotiating drug prices is common practice in other major markets, CMS had not previously held the legal authority to do so.
Express Pharma
JULY 27, 2024
On one hand, robust IPR protection is essential to incentivise research and development. It encourages pharmaceutical companies to invest heavily in discovering new drugs, developing innovative treatments, and improving healthcare outcomes. However, the flip side of the coin is equally important.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
SEPTEMBER 6, 2023
What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets. appeared first on Express Pharma.
PharmaShots
MAY 9, 2023
Sit back and relax, while the article unfolds before you, the magic model that is certain to revamp your company Achieving economic sustenance and ensuring smooth sailing even in unfavorable situations are two common dreams that every pharmaceutical company shares.
Pharmaceutical Technology
JUNE 29, 2022
Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. However, extended market exclusivity is often associated with high drug pricing and limited patient access.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.
pharmaphorum
AUGUST 27, 2020
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies.
Expert insights. Personalized for you.
52 
Let's personalize your content